CADTH pan-Canadian oncology drug review recently released its initial clinical guidance report for the use of avastin for platinum-resistant ovarian cancer. Along with the clinical review they have released the initial economic guidance report and the initial pERC recommendation.
Read the initial clinical guidance report here.
Read the initial economic guidance report here.
Read the initial pERC recommendations here.
No comments:
Post a Comment